EGFR and neoplasm: Therapeutically, combination of EGFR-TKI with ACh/M3R signaling inhibition using the FDA-approved drug darifenacin impeded tumor relapse in mice, demonstrating a prospective combination therapeutic strategy to manipulate the emergence of drug tolerance.